<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1400074&amp;fmt=gif">

Press Releases

Jump to a page: News Media Kit

Biodesix Named Company of the Year by Colorado BioScience Association

Biodesix, Inc. has been named Company of the Year by the Colorado BioScience Association (CBSA). The company was honored at the 16th Annual CBSA Awards Dinner on November 7, 2019.

AVEO Oncology and Biodesix Announce Initiation of the CyFi-2 Study

AVEO Oncology and Biodesix Announce Initiation of the CyFi-2 Study, a Phase 2 Randomized Study of Ficlatuzumab in Combination with High-Dose Cytarabine vs. High-Dose Cytarabine Alone in Patients with Relapsed and Refractory AML.

Biodesix Appoints Scott Hutton as Chief Executive Officer

Biodesix, Inc., the leader in lung cancer diagnostic solutions, today announced that current Chief Operating Officer Scott Hutton will become Chief Executive Officer on January 1, 2020.

Biodesix Announces First System-Wide Integration of Nodify XL2 Testing for Lung Nodule Management

Biodesix, Inc. today announced that Tri-Star Health in Nashville, TN is the first hospital system in the U.S. to adopt the recently launched Nodify XL2™ proteomic nodule classifier for incidental lung nodule management.

Biodesix Completes Acquisition of Oncimmune Assets in the United States

Biodesix, Inc., today announced that it has completed acquisition of Oncimmune’s laboratory and incidental pulmonary nodule (IPN) malignancy test in the United States.

Biodesix Names Dr. James Jett Chief Medical Officer

Biodesix, Inc. the leader in lung cancer diagnostics, today announced the appointment of internationally recognized lung cancer expert, James Jett, M.D., as Chief Medical Officer.

Biodesix Secures U.S. Patent for Proprietary Blood Specimen Collection Device

Biodesix, Inc., today announced it has been issued U.S. Patent Number 10,422,729, which covers the Biodesix Collection Device (BCD). The new device offers improved ease of use in blood sample collection for diagnostic testing, compared to current standard methods.

Biodesix Highlights Pipeline and Companion Diagnostic Development at World CDx and RAS-Targeted Drug Discovery

Biodesix highlighted the company’s capabilities in the development and commercialization of companion diagnostics aimed at directing the treatment of non-small cell lung cancer (NSCLC) at the 2019 Clinical Biomarkers & World CDx Conference.

Biodesix Announces New Clinical Data Demonstrating VeriStrat Testing Predicts Survival in Advanced NSCLC and Immunotherapy

Biodesix, Inc. this week highlighted findings from multiple studies demonstrating the significance and clinical utility of its VeriStrat® blood-based proteomic test.

Biodesix Adds Dr. Robert Georgantas III to Executive Leadership Team

Biodesix announced a biomarker research collaboration with Checkmate Pharmaceuticals, using Biodesix's proprietary discovery platform, the Diagnostic Cortex